Developing precision immunotherapy for value-based treatment of lung cancer in India

Emory Vaccine Centre0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年5月30日

试验速览

暂无简介。

•1. Male or female at age 18-75 years.
•2. Confirmed pathological diagnosis of NSCLC.
•3. Eastern Co-operative Oncology Group (ECOG) performance status 0-2.
•4. After multidisciplinary tumor board discussion, being considered for:
•4a. Upfront surgical resection (stage 1-3A disease)
•4b. Neoadjuvant chemotherapy followed by surgical resection (mostly stage 3 A disease)
•4c. Neoadjuvant immunotherapy followed by surgical resection (mostly stage 3 A disease)
•4d. Stage 4 (metastatic) disease being considered for first line immunotherapy based on PD-L1 TPS (Tumor proportion score) >=50%.
•5.Willing to continue treatment and follow up at any of the participating clinical sites (TMC or AIIMS)

•1. Pregnant or lactating women.
•2. Congenital or acquired immunodeficiency disorders.
•3. Active autoimmune disorders requiring >10 mg of prednisone or dose equivalent. Hypothyroidism requiring only hormone replacement
•would be allowed.
•4. Patients with untreated or symptomatic brain metastasis.
•5. Hepatitis B or C infections.

发起方

Emory Vaccine Centre